BioMarin Isn't a "Gene Therapy Company"

BioMarin Pharmaceuticals (NASDAQ:BMRN) started the year with a slow first quarter coming in under its 15% growth target, but management still feels like the company is in a good position to hit its previously announced 2019 revenue guidance, with sales of Palynziq ramping up and lumpy sales of its other drugs eventually averaging out.